IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 306 filers reported holding IONIS PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.70 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,797,500 | +7.0% | 105,765 | -3.2% | 0.02% | +15.4% |
| Q2 2023 | $4,484,989 | +8.9% | 109,310 | -5.2% | 0.01% | +8.3% |
| Q1 2023 | $4,119,071 | -15.0% | 115,251 | -10.1% | 0.01% | -25.0% |
| Q4 2022 | $4,843,134 | -15.7% | 128,227 | -1.3% | 0.02% | -11.1% |
| Q3 2022 | $5,743,000 | +13.1% | 129,854 | -5.4% | 0.02% | +38.5% |
| Q2 2022 | $5,080,000 | +19.8% | 137,233 | +19.9% | 0.01% | +44.4% |
| Q1 2022 | $4,239,000 | +716.8% | 114,451 | +571.1% | 0.01% | +800.0% |
| Q4 2021 | $519,000 | -12.0% | 17,054 | -3.0% | 0.00% | 0.0% |
| Q3 2021 | $590,000 | -11.7% | 17,579 | +5.0% | 0.00% | 0.0% |
| Q2 2021 | $668,000 | -79.4% | 16,749 | -76.8% | 0.00% | -85.7% |
| Q1 2021 | $3,246,000 | -42.6% | 72,205 | -27.9% | 0.01% | -46.2% |
| Q4 2020 | $5,659,000 | +57.5% | 100,085 | +32.1% | 0.01% | +44.4% |
| Q3 2020 | $3,594,000 | -19.7% | 75,736 | -0.3% | 0.01% | -25.0% |
| Q2 2020 | $4,477,000 | +34.9% | 75,936 | +8.2% | 0.01% | +9.1% |
| Q1 2020 | $3,318,000 | -37.7% | 70,176 | -20.4% | 0.01% | -15.4% |
| Q4 2019 | $5,326,000 | -0.9% | 88,156 | -1.7% | 0.01% | -13.3% |
| Q3 2019 | $5,374,000 | -9.8% | 89,703 | -3.2% | 0.02% | -11.8% |
| Q2 2019 | $5,958,000 | +213.9% | 92,702 | +296.5% | 0.02% | +240.0% |
| Q1 2019 | $1,898,000 | +46.6% | 23,381 | -2.4% | 0.01% | +25.0% |
| Q4 2018 | $1,295,000 | +4.8% | 23,961 | 0.0% | 0.00% | +33.3% |
| Q3 2018 | $1,236,000 | +21.3% | 23,961 | -2.0% | 0.00% | 0.0% |
| Q2 2018 | $1,019,000 | -6.7% | 24,461 | -1.3% | 0.00% | 0.0% |
| Q1 2018 | $1,092,000 | -14.4% | 24,771 | -2.3% | 0.00% | 0.0% |
| Q4 2017 | $1,275,000 | +0.1% | 25,344 | +0.8% | 0.00% | -25.0% |
| Q3 2017 | $1,274,000 | +1.8% | 25,135 | +2.1% | 0.00% | 0.0% |
| Q2 2017 | $1,252,000 | +29.5% | 24,616 | +2.3% | 0.00% | 0.0% |
| Q1 2017 | $967,000 | -69.3% | 24,066 | -63.5% | 0.00% | -71.4% |
| Q4 2016 | $3,153,000 | +11.7% | 65,917 | -14.4% | 0.01% | +27.3% |
| Q3 2016 | $2,822,000 | +51.4% | 77,030 | -3.7% | 0.01% | +37.5% |
| Q2 2016 | $1,864,000 | +360.2% | 80,030 | +700.3% | 0.01% | +300.0% |
| Q1 2016 | $405,000 | – | 10,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tweedy, Browne Co LLC | 3,541,136 | $133,749 | 7.12% |
| Bellevue Group AG | 9,743,900 | $368,027,103 | 4.88% |
| M28 Capital Management LP | 126,300 | $4,770,351 | 4.55% |
| Sicart Associates LLC | 246,258 | $9,301,165 | 3.28% |
| Camber Capital Management LP | 1,925,000 | $72,707 | 2.49% |
| Privium Fund Management B.V. | 148,807 | $5,557,941 | 2.11% |
| Deep Track Capital, LP | 1,205,773 | $45,542,046 | 1.91% |
| BVF INC/IL | 1,121,809 | $42,370,726 | 1.79% |
| Orbimed Advisors | 1,993,600 | $75,298,272 | 1.44% |
| Parkman Healthcare Partners LLC | 141,115 | $5,329,914 | 1.42% |